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Background: There have been several reports describing the 
capability of ginseng extracts as an adjuvant. In this study, 
we tested if ginsan, a polysaccharide extracted from Panax 
ginseng, was effective in enhancing antibody response to or-
ally delivered Salmonella antigen. Methods: Ginsan was 
treated before oral salmonella antigen administration. 
Salmonella specific antibody was determined by ELISA. 
mRNA expression was determined by RT-PCR. Cell migra-
tion was determined by confocal microscopy and flow 
cytometry. COX expression was detected by western blot. 
Results: Ginsan treatment before oral Salmonella antigen 
delivery significantly increased both secretory and serum an-
tibody production. Ginsan increased the expression of COX 
in the Peyer’s patches. Various genes were screened and we 
found that CCL3 mRNA expression was increased in the 
Peyer’s patch. Ginsan increased dendritic cells in the Peyer’s 
patch and newly migrated dendritic cells were mostly found 
in the subepithelial dome region. When COX inhibitors were 
treated, the expression of CCL3 was reduced. COX inhibitor 
also antagonized both the migration of dendritic cells and the 
humoral immune response against oral Salmonella antigen. 
Conclusion: Ginsan effectively enhances the humoral im-
mune response to orally delivered antigen, mediated by 
CCL3 via COX. Ginsan may serve as a potent vaccine sup-
pliment for oral immunization.
[Immune Network 2010;10(1):5-14]
INTRODUCTION
Most of the currently available vaccines are licensed for use 
only via a nonmucosal route, usually involving subcutaneous 
or  intramuscular  inoculation  (1).  Parenteral  vaccines  elicit 
predominantly  systemic  immune  responses  that  are  usually 
unable  to  prevent  the  initial  interaction  step  between  the 
pathogen and the host (2). As the most effective means of 
inducing an immune response at a specific effector site is lo-
cal stimulation at a related inductive site, oral vaccination rep-
resents one of the most promising vaccination strategy to pre-
vent  gastrointestinal  infections.
    Polysaccharides  isolated  from  botanical  sources  (mush-
rooms, algae, lichen and higher plants) have attracted a great 
deal of biomedical attention because of their broad spectrum 
of  therapeutic  properties  and  relatively  low  toxicity  (3,4). 
Among numerous plant polysaccharides, ginseng is a slow- 
root growing herb that has been used medicinally for more 
than  3,000  years  by  practitioners  of  oriental  medicine  (5). 
There have been several reports describing the immune ad-
juvant capability of ginseng extracts. Immunization using por-
cine parvovirus vaccines utilizing single purified ginsenosides 
as an adjuvant stimulates the potent production of antibody, 
whose titer matches or exceeds that produced from the use 
of vaccines administered with aluminum hydroxide as the ad-
juvant (6). Ginseng extract is a well-tolerated adjuvant, and 
displays a superior adjuvant effect when used for immuniza-Ginsan Enhances Humoral Antibody Response to Orally Delivered Antigen
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tion against Staphylococcus aureus in dairy cattle (7). Thus, 
the use of ginseng as a co-adjuvant provides a simple, well 
tolerated  and  inexpensive  alternative  for  improving  the  po-
tency of aluminum hydroxide-based vaccine adjuvants (8). In 
a clinical study, ginseng significantly reduced the frequency 
of influenza or common cold, and natural killer cell activity 
levels were nearly twice as high in the ginseng group than 
in  the  placebo  group  (9).
    Ginsan is a soluble polysaccharide extracted from the roots 
of Panax ginseng (10). Various functions of ginsan as biologic 
modifiers have been reported (10-15). Recently, we have re-
ported that ginsan can modulate mucosal immune response 
in asthma model (16) and bacterial infection (17). However, 
its  possibility  as  a  mucosal  vaccine  adjuvant  has  not  been 
studied. In this study, we studied the potential of ginsan as 
an  adjuvant  for  oral  immunization  using  paraformaldehyde 
fixed  Salmonella  typhimurium a s  a n  a n t i g e n .
MATERIALS AND METHODS
Animals and material
BALB/c  mice  were  purchased  from  KOATECH  (DaeJeon, 
Korea).  Coral  green  fluorescent  protein  (cGFP)  transgenic 
mice in a BALB/c background were kindly provided by Dr. 
Kwon  (International  Vaccine  Institute,  Seoul,  Korea).  The 
mice were subsequently bred at Chonnam National University 
in chambers maintained at 22∼23
oC with equal 12 h periods 
of  light  and  dark  each  day.  The  Cyclooxygenase  (COX)-1- 
specific inhibitor SC-560 (Cayman Chemical, Ann Arbor, MI, 
USA) and the non-specific COX-1 inhibitor acetylsalicylic acid 
(ASA; Sigma-Aldrich, St. Louis, MO, USA) dissolved in ethanol 
were  used.  TRIzol  reagent  was  purchased  from  Invitrogen 
(Carlsbad, CA, USA) and primers were obtained from Bionics 
(Seoul, Korea). All experiments using mice were followed the 
guideline approved by the Committee for the Care and Use 
of  Laboratory  Animals  at  Chonnam  National  University.
Preparation of ginsan
The ginsan polysaccharide was purified from the ethanol in-
soluble  fraction  of  the  aqueous  P.  ginseng  extract  as  de-
scribed previously (15). Further purification was carried out 
successively using size exclusion and ion exchange column 
chromatography.  Nuclear  magnetic  resonance  analysis  re-
vealed that the purified fraction was composed of α(1→6) 
glucopyranoside and β(2→6) fructofuranoside in a 5：2 mo-
lar ratio. The endotoxin level in the purified ginsan prepara-
tion  was  less  than  0.03  EU/mg  as  measured  using  the 
Endosafe
TM  Limulus  amebocyte  lysate  assay  (Charles  River 
Laboratories, Wilmington, MA, USA) according to the manu-
facturer's instructions.  The  purified  ginsan was  dissolved  in 
phosphate buffered saline (PBS; pH 7.4) and filtered through 
a  0.22μm  Millipore  membrane  (Millipore,  Billerica,  MA, 
USA).
Ginsan and COX inhibitor treatments
Ginsan (100 mg/kg) was intraperitoneally introduced to the 
mice  once  a  day  for  two  days  before  oral  antigen  admini-
stration.  COX  inhibitors,  SC-560  (5  mg/kg)  and  ASA  (100 
mg/kg),  were  orally  administered  on  the  same  day  ginsan 
treatment was done (16). To continuously suppress COX, or-
ally vaccinated mice were fed with indomethacin (30μg/ml) 
dissolved  in  drinking  water.
Immunization of mice
Salmonella typhimurium were grown to late log phase in LB 
broth  at  37
oC  with  vigorous  aeration.  For  immunization,  S. 
typhimurium  was  fixed  with  4%  paraformaldehyde  (Sigma- 
Aldrich) for 30 min and washed three times with sterile PBS. 
Mice fasted overnight were orally immunized with 1×10
9 col-
ony  forming  units  of  S.  typhimurium  suspended  in  500μl 
PBS  using  oral  zonde  needle.  Mice  were  immunized  twice 
during  a  two  week  interval.
Measurement of antibody by enzyme-linked immu-
nosorbent assay (ELISA)
Samples  were  taken  from  each  group  of  immunized  mice. 
Stool samples collected by isolating each mouse in a dark box 
for 10 minutes before other procedures. Blood samples were 
collected by cardiac puncture of mice anaesthetized with ket-
amine (100 mg/kg) 14 days after the second immunization. 
Vaginal lavage fluids were obtained by gentle flushing of the 
mouse vagina with 100μl of sterile PBS. Lavage fluids were 
then centrifuged and the supernatants were analyzed for anti-
gen-specific antibody content. Serum, saliva, stool and vagi-
nal lavage samples were stored at −20
oC until ELISA. Briefly, 
96-well microplates (Corning, Corning, NY, USA) were coated 
with 50μl of whole S. typhimurium cell lysate dissolved in 
PBS  overnight.  The  plates  were  blocked  with  1%  BSA 
(Sigma-Aldrich) in PBS to avoid non-specific binding. A vol-
ume of 50μl of each diluted sample was added to the plates, 
incubated at room temperature for 2 h, and then the plates 
were  washed.  Horseradish  peroxidase  conjugated  goat  an-Ginsan Enhances Humoral Antibody Response to Orally Delivered Antigen
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ti-mouse IgA secondary antibody (Sigma-Aldrich), IgG1 (BD 
Pharmingen) or IgG2 (BD Pharmingen) was then added and 
incubated for 1 h at room temperature. o-Phenylenediamine 
dihydrochloride (0.4 mg/ml; Sigma-Aldrich) in 0.05 M phos-
phate citrate buffer was used as the substrate. The absorb-
ance was measured at 490 nm in an ELISA reader (Molecular 
Devices,  Sunnyvale,  CA,  USA).
Western blot analysis
The  activation  of  COX-1  and  COX-2  in  Peyer's  patch  and 
ileum  was  observed  24  h  following  ginsan  treatment  by 
Western  blot.  Proteins  were  probed  with  monoclonal  an-
ti-COX-1,  anti-COX-2,  or  anti-beta-actin  antibody  at  a  1：
1,000  or  1：5,000  dilution.  Horseradish  peroxidase-linked 
secondary antibodies were used at a 1：1,000 dilution. Signal 
detection was carried out using a LAS-3000 scanning imager 
(Fujifilm,  Tokyo,  Japan).
Reverse transcriptase-polymerase chain reaction (RT- 
PCR)
Expression  levels  of  RNA  transcripts  were  quantified  using 
R T - P C R .  T o t a l  R N A  f r o m  t h e  P e y e r ' s  p a t c h e s ,  s p l e e n  a n d  
ileum were isolated using TRIzol reagent (Invitrogen). RNA 
(2μg/tube) was reverse transcribed into cDNA for 45 min at 
40
oC using Superscript RT (Promega, Madison, WI, USA) in 
the presence of 1μl random primer (Promega). The cDNA 
was  used  as  a  template  for  PCR  amplification  (Eppendrof, 
Westbury,  NY,  USA).  The  reaction  mixture  consisted  of  10 
mM  Tris-HCl  (pH  8.3),  50  mM  KCl,  2  mM  MgCl2,  200μM 
dNTP (TaKaRa Bio, Shiga, Japan), 0.5 U Taq DNA polymer-
ase (TaKaRa Bio), and 0.05 mM of each primer. The primers 
used  were  as  follows:  CCL3  sense,  5’-AACATCATGAAGG-
TCTCCAC-3’,  CCL3  antisense,  5’-CCAAGACTCTCAGGCATT-
CA-3’,  CCL4  sense,  5’-GTTCTCAGCACCAATGGGCTCTGA-3’, 
CCL4 antisense, 5’-CTCTCCTGAAGTGGCTCCTCCTG-3’, CCL5 
sense,  5’-GGTACCATGAAGATCTCTGCA-3’,  CCL5  antisense 
5’-AAACCCTCTATCCTAGCTCAT-3’, CCL7 sense, 5’-TCTGTG-
CCTGCTGCTCATAG-3’,  CCL7  antisense,  5’-CTTTGGAGTT-
GGGGTTTTCA-3’, CCL8 sense, 5’-CCTTCAACATGAAGATCT-
ACGCA-3’,  CCL8  antisense,  5’-AACTCAGGTGTGAAGGTTC-
AAG-3’,  CCL9  sense,  5’-ATCACACATGCAACAGAGACAAAA- 
3’,  CCL9  antisense,  5’-TTATTGTTTGTAGGTCCGTGGTTG-3’, 
CCL20 sense, 5’-TGCTCTTCCTTGCTTTGGCATGGGTA-3’, CCL20 
antisense, 5’-TCTGTGCAGTGATGTGCAGGTGAAGC-3’, CCL21 
sense,  5’-ATGGCTCAGATGATGACTCT-3’,  CCL21  antisense, 
5’-TACTGGGCTATCCTCTTGA-3’,  CCL25  sense,  5’-TCACTA-
TGAAACTGTGCCTTTTTG-3’,  CCL25  antisense,  5’-CTTAATT-
GTTGGTCTTTCTGGGC-3’,  COX-1  sense,  5’-AGGAGATGG-
CTGCTGAGTTGG-3’,  COX-1  antisense,  5’-AATCTGACTTTC-
TGAGTTGCC-3’,  COX-2  sense,  5’-ACACACTCTATCACTGG-
CACC-3’, COX-2 antisense, 5’-TTCAGGGAGAAGCGTTTGC-3’, 
β-actin  sense,  5’-TCATGAAGTGTGACGTTGACATCCGT-3’, 
and  β-actin  antisense,  5’-CTTAGAAGCATTTGCGGTGCAC-
GATG-3’.
    The  thermal  cycle  conditions  were  94
oC  for  1  min,  55
oC 
for 30 s, and 72
oC for 30 s for 35 cycles. PCR products were 
electrophoresed  on  2%  agarose  gels.
Adoptive transfer of GFP positive splenocyte
Splenocytes  were  isolated  from  cGFP-positive  mice.  Single 
cell suspensions were obtained by gently chopping the tissues 
with the needles of a 1 ml syringe and suspending the cells 
in RPMI 1640 containing 10% fetal bovine serum (FBS). After 
washing, each cell suspension was subjected to gradient cen-
trifugation  by  overlaying  5  ml  volumes  on  5  ml  Lympho-
prep
TM ( 1 . 0 7 7  g / m l ;  N y c o m e d  P h a r m a ,  O s l o ,  N o r w a y )  a n d  
spinning at 400 ×g for 15 min at room temperature as recom-
mended by the manufacturer. Interface cells were collected, 
washed in RPMI 1640, resuspended, and the number of viable 
cells was determined using the Trypan blue exclusion assay. 
Splenocytes (1×10
7) were transferred to the syngenic Balb/c 
mice  through  the  caudal  vein  in  100μl  of  RPMI  1640.
Confocal microscopy of Peyer’s patches
Tissues were embedded in Tissue-Tek OCT compound (Miles 
Scientific, Naperville, IL, USA) and stored at −80
oC. Cryosec-
tions 10μm in thickness were fixed in ethanol and co-stained 
for phenotypic markers. Antibodies used for the phenotypic 
markers  were  as  follows:  CD11c  (BD  Pharmingen),  CD3 
(R&D Systems, Minneapolis, MN, USA), B220 (R&D Systems), 
and CCL3 (R&D Systems). All were visualized with Alexa-488 
labeled or Alexa-596 labeled secondary antibody (Molecular 
Probes, Eugene, OR, USA). The tissues were mounted with 
a Slowfade
TM antifade kit (Molecular Probes) and visualized 
using  a  Radiance  2100  confocal  laser  scanning  microscope 
(Bio-Rad,  Hercules,  CA,  USA).
Cell preparation and flow cytometric analysis
Peyer's patches were removed from small intestines. Single 
cell  suspensions  were  obtained  as  described  earlier  in  the 
text. The cells were pooled and poured through a 100μm 
nylon mesh (Millipore) prior to centrifugation for 15 min at Ginsan Enhances Humoral Antibody Response to Orally Delivered Antigen
Hee Sam Na, et al.
8 IMMUNE NETWORK http://www.ksimm.or.kr Volume 10 Number 1 February 2010
Figure 1. Ginsan induces higher humoral immune response against paraformaldehyde fixed S. typhimurium. BALB/c mice immunized with 1×10
9
colony forming units fixed Salmonella twice each week for two weeks. Ginsan was applied one day before oral immunization. Two weeks
after the final immunization, the mice were sacrificed and saliva, vaginal wash, stool and serum were obtained. (A) Salmonella specific IgG
in serum. (B) Salmonella specific IgA in saliva, vaginal flush or stool. Each group consists of five mice (*p＜0.05).
400 ×g. Cells were incubated on ice for 30 min in Fc block 
c o n s i s t i n g  o f  5 %  m o u s e  s e r u m  ( S i g m a )  a n d  5 μg/ml  an-
ti-mouse  CD32/CD16  (BD  Pharmingen)  in  the  presence  of 
phycoerytherin-conjugated  CD11c  (BD  Pharmingen).  After 
staining, cells were washed and analyzed by flow cytometry 
with FACScan (Becton Dickson, Franklin Lakes, NJ, USA) and 
analyzed  using  CellQuest  software  (Becton  Dickson).
Statistical analysis
Data  analysis  was  performed  with  SPSS  software  (SPSS, 
Version 17, SPSS Inc., Chicago, IL, USA). Student’s t-test and 
ANOVA  were  used  to  compare  the  parameters  between 
groups.  Values  of  p＜0.05  were  considered  significant.
RESULTS
Effect of ginsan on adaptive mucosal immune res-
ponse to orally administered antigen
Given the descriptions of ginseng extracts as being a potent 
vaccine adjuvant (6-8), we initially tested whether ginsan was 
likewise  a  potent  adjuvant  to  orally  administered  antigens. 
Mice were pretreated twice with ginsan before oral immuniza-
tion twice weekly for two weeks. Two weeks after the sec-
ond  immunization,  specific  antibodies  against  Salmonella 
were determined from serum, saliva, vaginal fluid and stool. 
Ginsan treated mice produced significantly higher amounts of 
serum IgG1 and IgG2 (Fig. 1A), as well as secretory IgA in 
all  samples  (Fig.  1B).
Effect of ginsan on COX expression in the Peyer’s 
patch
Recently,  we  have  reported  that  ginsan  modulates  the  ex-
pression  of  COX.  Ginsan  treatment  suppressed  allergic  re-
action in murine asthma model (16) and it was also effective 
in protecting the host from pathogenic bacterial infection via 
nasal route (17). Since both models were related with mu-
cosal organs, we speculated that ginsan may also modulate 
COX expression in the Peyer's patch. Ginsan also specifically 
enhanced  the  mRNA  expression  of  COX-1  and  COX-2  in 
Peyer's patches  (Fig.  2A)  and it  was  confirmed by western 
blot  examination  (Fig.  2B).
Effect of ginsan on mRNA expression in Peyer's pa-
tches, ileum and spleen
Next, we examined various genes to elucidate the mechanism 
of ginsan. Among various genes, ginsan specifically increased 
the  expression  of  CCL3  in  the  Peyer's  patches,  while  ex-
pression was decreased both in the spleen and nearby ileum. 
Expression of some chemokine ligands were rather decreased 
following ginsan treatment (Fig. 3). Since CCL3 is related with 
dendritic  cell  (DC)  migration  (18,19),  other  chemokine  li-
gands related with DC migration were screened. There were 
no changes in the expression of other genes related with DC 
migration  in  the  Peyer's  patches.
    To  determine  CCL3  expressing  cells  within  the  Peyer's 
patches, frozen sections were stained with anti-CCL3 in com-
bination  with  CD11c.  CCL3  was  present  within  the  sub-Ginsan Enhances Humoral Antibody Response to Orally Delivered Antigen
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Figure 2. Effect of ginsan on COX expression in Peyer's patches. (A) 
Semi-quantitative RT-PCR for COX-1 and COX-2 mRNA from the 
Peyer's patches. Total RNA was isolated and used for RT-PCR. PCR 
products were visualized on 2% agarose gel using ethidium bromide.
(B) Western blotting of COX-1 and COX-2 in the Peyer's patch and
ileum. Increased COX-1 expression was evident using both appro-
aches.
Figure 3. Effect of ginsan on various chemokine mRNA expression. 
Semiquantitative RT-PCR analysis of CCL expression in the Peyer's 
patch, spleen and ileum were analyzed. Total RNA isolated following
ginsan treatment was used for RT-PCR. PCR products were visualized
on 2% agarose gel using ethidium bromide. Ginsan specifically 
enhanced CCL3 expression in the Peyer's patch.
epithelial  dome  region  and  CCL3  expression  was  markedly 
increased  following  ginsan  treatment  (Figs.  4A∼D),  con-
sistent  the  RT-PCR  results.
Characterization of splenocytes migrating to the 
Peyer's patches
To determine the effect of ginsan on the DC population in 
the Peyer's patch, mice were sacrificed 24 h after ginsan treat-
ment  and  the  Peyer's  patches  were  collected  for  flow  cy-
tometry  analysis.  Ginsan  treatment  significantly  increased 
CD11c  positive  cells  in  the  Peyer's  patch  compared  to  the 
c on t ro l g r ou p (F i g . 5A ).  T o de t er mi ne  if g in san  mo d ul at ed 
DC migration, splenocytes from cGFP transgenic mice were 
intravenously introduced 24 h after ginsan treatment. The fol-
lowing  day,  Peyer's  patches  were  prepared  for  immuno-
fluorescence analysis of the GFP splenocyte migration. Con-
sistent with the flow cytometry results, immunofluorescence 
revealed ginsan-mediated enhanced migration of GFP spleno-
cytes to the Peyer's patches (Fig. 5B). Most of the migrated 
cells were found near the subepithelial dome of the Peyer's 
p a t c h  w h e r e  D C  a r e  m o r e  p r e v a l e n t  ( F i g .  5 C ) .  T h e  r e s u l t s 
are consistent with the suggestion the ginsan can enhance the 
migration  of  CD11c-positive  splenocytes  to  the  Peyer's  pa-
tches.
Effect of ginsan and COX inhibitors on CCL3 ex-
pression in Peyer's patches
To test the role of COX on CCL3 expression regulation, mice 
were treated in combination with ginsan and COX inhibitors. 
Semi-quantitative RT-PCR for CCL3 mRNA in the Peyer's patch 
was  determined  following  various  treatments.  The  specific 
COX-1  inhibitor  SC-560  moderately  reduced  the  ginsan-en-
hanced CCL3 expression (Fig. 6A). ASA, a nonspecific COX 
inhibitor,  mostly  reduced  the  CCL3  expression  induced  by 
ginsan (Fig. 6B). However, single SC-560 or ASA did not to-
tally suppress CCL3 expression suggesting that physiological 
C C L 3  e x p r e s s i o n  m a y  b e  r e g u l a t e d  b y  s o m e  o t h e r  m e c h a -
nism.
Effect of ginsan and COX inhibitor on GFP sple-
nocyte migration to the Peyer's patches
To determine the effect of ginsan and COX inhibitor on sple-
nocyte  migration,  GFP  splenocytes  were  intravenously  in-
troduced to mice pretreated with ginsan or ASA. Since COX-1 
inhibition  can  upregulate  COX-2  expression  (20),  ASA  was 
used to suppress both COX-1 and COX-2. Twenty-four hours 
after  GFP  splenocyte  delivery,  mice  were  sacrificed  and Ginsan Enhances Humoral Antibody Response to Orally Delivered Antigen
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Figure 4. Localization of CCL3 in 
the Peyer's patches. Frozen sections
of Peyer's patches were doubly 
stained with antibodies against 
CD11c (green) in combination with 
anti-CCL3 (red). Panels (A) and (C) 
display the controls, and panels (B) 
and (D) display the ginsan treat-
ment. (A, B ×600; C, D ×1,800).
P e y e r ' s  p a t c h e s  w e r e  c o l l e c t e d  f o r  f l o w  c y t o m e t r y  a n a l y s i s .  
Ginsan  treatment  increased  both  GFP  positive  and  CD11c 
positive  cells  compared  to  the  control  group.  ASA  antago-
nized the effect of ginsan, reducing both CD11c cells and the 
migration of GFP positive cells (Fig. 7). Consistent with the 
C C L 3  m R N A  e x p r e s s i o n  r e s u l t ,  t r e a t m e n t  w i t h  j u s t  A S A  d i d 
not totally reduce the population of CD11c or the migration 
of  DCs  to  the  Peyer's  patches.
Effect of ginsan and COX inhibitor on antibody 
response to oral immunization
Finally,  antibody  responses  to  oral  immunization  were 
determined. Ginsan treated mice produced significantly high-
er antibody titers both in stool and serum compared to that 
the control group. ASA suppressed antibody production in-
duced by ginsan. Treatment just with ASA did not influence 
systemic antibody response, but decreased the amount of se-
cretory  IgA  antibody  compared  to  other  groups  (Fig.  8).
DISCUSSION
In this study, we tested if ginsan, a polysaccharide extracted 
from  Panax  ginseng,  is  effective  in  enhancing  the  antibody 
response to orally administered antigens. Ginsan significantly 
increased both secretory and serum antibodies to orally ad-
ministered antigens suggesting that it modulates antibody re-
sponse  to  mucosally  introduced  antigens.
    Peyer's patches are the inductive site for the adaptive im-
mune response to intestinal antigens (21). Foreign antigens 
in the gut lumen are transported to the Peyer's patches by 
specialized epithelial cells called M cells (22). The incoming 
antigens are sampled by the DCs and this sampling of antigen 
is believed to be critical to the induction of adaptive mucosal 
immunity (23). Mice defective in CCR6 lack CD11b＋/CD11c＋ 
cells  in  the  subepithelial  dome  of  the  Peyer's  patches  and 
show  an  impaired  humoral  immune  response  to  orally  ad-
ministered antigens (24). In this study, ginsan increased the Ginsan Enhances Humoral Antibody Response to Orally Delivered Antigen
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Figure 5. Analysis of the migration of splenocytes to the Peyer’s patches. (A) Ginsan treatment significantly enhanced CD11c positive cell numbrs
in the Peyer's patch. (*p＜0.05) (B) BALB/c mice were pretreated with ginsan for two days. GFP splenocytes (5×10
6) were then intraveneously
introduced. To determine migration of the splenocytes, Peyer's patches were fixed and examined. Ginsan treatment greatly enhanced migration
of GFP splenocytes to the subepithelial dome of Peyer's patches. (C) Newly migrating cells were mostly found near CD11c positive cells.
Figure 6. Effect of ginsan and COX-1 specific inhibitor (A) or 
non-specific COX-inhibitor (B) on the expression of CCL3 mRNA in
Peyer's patches. Total RNA was isolated and used RT-PCR can was 
prepared by reverse transcription. The PCR products were visualized 
on 2% agarose gel using ethidium bromide. CCL3 expression was 
antagonized by SC-560 and aspirin (ASA) treatment. (Ct, PBS; Gs, 
Ginsan; Sc, SC-560; ASA).
population of DCs in the Peyer's patches and also enhanced 
the humoral immune response to orally administered Salmon-
ella antigen. However, CCR6 expression was not influenced 
by  ginsan  treatment.
    We have previously reported that ginsan modulates COX 
expression in the lung and nasal associated lymphoid tissues. 
In murine asthma model, ginsan suppressed the allergic re-
action  by  up-regulating  COX  expression  that  is  down-regu-
lated upon allergen challenge (16). Likewise, when V. vulnifi-
cus was nasally challenged, it suppresses COX expression and 
ginsan maintained the COX expression (17). In both model, 
ginsan modulated the expression of COX at the effector site 
which  is  the  mucosal  system.
    Therefore, we hypothesized that ginsan may also have in-
fluenced the COX expression in the Peyer's patch. The ex-
pression  of  COX  was  distinctively  increased  in  the  Peyer's 
patch of ginsan treated mice. In a septic mouse model, ginsan 
significantly decreases the proinflammatory cytokines includ-
ing  tumor  necrosis  factor-alpha,  interleukin  (IL)-1β,  IL-6, Ginsan Enhances Humoral Antibody Response to Orally Delivered Antigen
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Figure 7. Effect of ginsan and COX inhibitor on cell migration to the Peyer's patches. Cells from Peyer's patches were prepared following various
treatments and GFP splenocyte transfer. Cells were stained with antibodies against CD11c. CD11c cells were increased following ginsan treatment,
which was antagonized by ASA treatment (*p＜0.05).
Figure 8. Effect of ginsan and COX inhibitor on Salmonella-specific Ig following oral immunization. Each group was orally immunized with
paraformaldehyde-fixed  S. typhimurium. (A) Salmonella specific IgG in serum. (B) Salmonella specific IgA in stool (*p＜0.05).
IL-12, IL-18 and interferon-alpha (10), strongly supporting that 
ginsan does not induce pathologic inflammatory response in 
the  recipient.
    To  understand  the  relation  between  COX  expression  en-
hanced antibody response to orally administered antigen, var-
ious  genes  related  with  cell  migration,  B  cell  or  T  cell  re-Ginsan Enhances Humoral Antibody Response to Orally Delivered Antigen
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sponses were screened. Among various genes, the expression 
of CCL3 was distinctively increased in the Peyer's patch fol-
lowing ginsan treatment. CCL3 is a potent chemoattractant for 
monocytes (25), natural killer cells (26), eosinophils (27) and 
DCs (18,19). When CCL3 is administered to mice, it induces 
m o b i l i z a t i o n  o f  D C  p r e c u r s o r s  i n t o  t h e  c i r c u l a t i o n  ( 2 8 ) .  
Furthermore, when CCL3 was nasally inoculated with ovalbu-
min, higher antibody titers of IgG and IgA are detected sug-
gesting CCL3 can enhance both systemic adaptive and mu-
cosal immunity (29). The enhanced expression of CCL3 at the 
Peyer's patches induced by ginsan may be responsible for the 
migration of DCs; alternatively, CCL3 expressing DCs could 
have  migrated  to  the  subepithelial  dome  of  the  Peyer's 
patches.
    Expression  of  other  chemokines  were  either  down-regu-
lated  or  unchanged.  Ginsan  treatment  decreased  the  ex-
pression of CCL5 in the spleen and ileum and CCL8 in the 
P e y e r ' s  p a t c h  a n d  i l e u m .  A l s o ,  e x p r e s s i o n  o f  C C L 2 1  a n d  
CCL25 were also decreased in the ileum in the ginsan treated 
group.  This  suggests  that  the  increased  expression  of  the 
CCL3 in the Peyer's patch is not likely due to a pathologic 
inflammatory response involving recruitment of lymphocytes 
t o  t h e  i n f l a m m a t o r y  f o c u s  ( 3 0 ) .
  To test the role of COX in modulating CCL3, COX was spe-
cifically inhibited by inhibited by SC-560 or nonspecifically in-
hibited by ASA. Both treatments reverted the expression of 
CCL3  to the  control  level.  However, additional  suppression 
was not observed suggesting that the regulation of the con-
stitutive expression of CCL3 may differ from that induced by 
ginsan. The migration of GFP splenocytes was also reversed 
by the COX inhibitors, as was both the systemic and mucosal 
immune  responses  enhanced  by  ginsan.  Treatment  solely 
with  COX  inhibitor  impaired  only  the  mucosal  immune  re-
sponse compared to the normal systemic immune response. 
In conclusion, ginsan enhances antibody response to orally 
introduced antigens by modulating the COX expression in the 
Peyer's patches. Enhanced COX expression increases DC mi-
gration to the Peyer's patch via CCL3. Since extracts from P. 
ginseng are wide used in the oriental medicine, these findings 
suggest that ginsan may serve as an efficient supplement for 
the  oral  vaccine.
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